Elevated Methylglyoxal: An Elusive Risk Factor Responsible for Early-Onset Cardiovascular Diseases in People Living with HIV-1 Infection
Viruses · 2025
DOI: 10.3390/v17040547 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, 2025. Verfasst von Mahendran Ramasamy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68130, USA. Hauptthemen laut MEDLINE: HIV Infections, Cardiovascular Diseases, Pyruvaldehyde. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 196 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NHLBI NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
People living with HIV (PLWH) develop cardiovascular diseases (CVDs) about a decade earlier and at rates 2–3 times higher than the general population. At present, pharmacological strategies to delay the onset of CVDs in PLWH are unavailable, in part because of an incomplete understanding of its molecular causes. We and others recently uncovered elevated levels of the toxic glycolysis and inflammation-induced byproduct methylglyoxal (MG) in plasma from PLWH and from HIV-infected humanized mice (Hu-mice). We also found a reduction in expression of the primary MG-degrading enzyme glyoxalase I (Glo-I) in autopsied cardiac tissues from HIV-1-infected individuals and HIV-1-infected Hu-mice. Increasing the expression of Glo-I in HIV-1-infected Hu-mice not only attenuated heart failure but also reduced endothelial cell damage, increased the density of perfused microvessels, prevented microvascular leakage and micro-ischemia, and blunted the expression of the inflammation-induced protein vascular protein-1 (VAP-1), key mediators of CVDs. In this narrative review, we posit that elevated MG is a contributing cause for the early onset of CVDs in PLWH. Pharmacological strategies to prevent MG accumulation and delay the development of early-onset CVDs in PLWH are also discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68130, USA.
- Department of Pharmacology, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia.
- Environment and Occupational Health, University of Nebraska Medical Center, Omaha, NE 68198, USA.
- Nebraska Redox Biology Center, Lincoln, NE 68503, USA.
- Center for Heart and Vascular Research, Omaha, NE 68198, USA.
ORCID-Profile: Zachary L Venn, Fadhel A Alomar, Ali Namvaran, Keshore R Bidasee
Förderung
- NIH HHS
- NHLBI NIH HHS
- NINDS NIH HHS
- Neuroscience Alliance Award
- National Institutes of Health (NIH)
Zitieren
APA
Ramasamy, M., Venn, Z. L., Alomar, F. A., Namvaran, A., Edagwa, B., Gorantla, S., & Bidasee, K. R. (2025). Elevated Methylglyoxal: An Elusive Risk Factor Responsible for Early-Onset Cardiovascular Diseases in People Living with HIV-1 Infection. Viruses. https://doi.org/10.3390/v17040547
Vancouver
Ramasamy M, Venn ZL, Alomar FA, Namvaran A, Edagwa B, Gorantla S, et al. Elevated Methylglyoxal: An Elusive Risk Factor Responsible for Early-Onset Cardiovascular Diseases in People Living with HIV-1 Infection. Viruses. 2025. doi:10.3390/v17040547
BibTeX
@article{Ramasamy2025,
author = {Ramasamy, Mahendran and Venn, Zachary L and Alomar, Fadhel A and Namvaran, Ali and Edagwa, Benson and Gorantla, Santhi and Bidasee, Keshore R},
title = {Elevated Methylglyoxal: An Elusive Risk Factor Responsible for Early-Onset Cardiovascular Diseases in People Living with HIV-1 Infection},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17040547}
}
EUVIMED